Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2002

01-04-2002 | Original Article

Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer

Authors: Edgardo Rivera, Vicente Valero, Francisco J. Esteva, Laura Syrewicz, Massimo Cristofanilli, Zia Rahman, Daniel J. Booser, Gabriel N. Hortobagyi

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2002

Login to get access
Metadata
Title
Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer
Authors
Edgardo Rivera
Vicente Valero
Francisco J. Esteva
Laura Syrewicz
Massimo Cristofanilli
Zia Rahman
Daniel J. Booser
Gabriel N. Hortobagyi
Publication date
01-04-2002
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2002
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-001-0405-3

Other articles of this Issue 4/2002

Cancer Chemotherapy and Pharmacology 4/2002 Go to the issue

Original Article

Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma

Original Article

Population pharmacokinetics of the novel anticancer agent KRN7000

Original Article

Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine)

Original Article

Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study

Original Article

XK469, a novel antitumor agent, inhibits signaling by the MEK/MAPK signaling pathway

Original Article

Effects of four Chinese herbal extracts on drug-sensitive and multidrug-resistant small-cell lung carcinoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits